Join
Live feed
·
PRReleasevia Quantisnow
Viatris Inc. logo

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

ByQuantisnow·Wall Street's wire, on your screen.
VTRS· Viatris Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VTRS (Viatris Inc.) and more on Quantisnow.